Clinical trials: Dengue Virus Infection
Leishmaniasis, Leptospirosis
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Zoonoses and arboviroses refer to a group of diseases transmitted from animals to humans, either directly or indirectly (via mosquitoes, ticks or contact with contaminated environments).
- Conditions
- Leishmaniasis, Leptospirosis, Brucellosis, Q Fever
- Trial name
- SEZAM (NCT06859619)
- Testing
- Peripheral venous blood sample
- Where
- France
- Volunteers
- 183 people
- Sponsor
- University Hospital, Montpellier
Dengue
Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
This study will evaluate the safety and immunogenicity of a tetravalent dengue vaccine TetraVax-DV TV005 in adults 50 to 70 years of age with no history of previous flavivirus infection.
- Trial name
- NCT02879266
- Testing
- TetraVax-DV TV005
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Sepsis
Immune Responses to Dengue and Sepsis
The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, influenza…
- Conditions
- Dengue, Sepsis, Influenza
- Trial name
- DEN-SEP (NCT07040202)
- Where
- 4 sites in Cambodia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Dengue
The Use of Biomarkers in Predicting Dengue Outcome
The burden of dengue infection has increased due to the current non-specific classification. A pilot study was conducted to evaluate the five of the biomarkers: neopterin, vascular endothelial growth factor (VEGF)…
- Trial name
- NCT02606019
- Where
- 2 sites in Malaysia
- Volunteers
- 108 people
- Sponsor
- Universiti Tunku Abdul Rahman
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.
- Trial name
- NCT01254422
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- Where
- 4 sites in Malaysia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Hemorrhagic Fever, Dengue Shock Syndrome
Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore
World Health Organisation (WHO) has identified Dengue as the fastest spreading mosquito-borne disease in the world. This study follows on from the National Medical Research Council STOP Dengue Translational and Clinical Research…
- Conditions
- Dengue Hemorrhagic Fever, Dengue Shock Syndrome, Severe Dengue
- Trial name
- NCT04048837
- Where
- 3 sites in Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
DENV-3 Controlled Human Infection Model
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
- Trial name
- NCT06799741
- Testing
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue Vaccines
Passive Safety Surveillance Data of Dengue Vaccine, Qdenga (TAK 003) in Private Vaccination Sites in Buenos Aires, Argentina.
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals from 4 years old and without limit of age.
- Trial name
- NCT06898775
- Where
- Argentina
- Volunteers
- 112,345 people, healthy volunteers welcome
- Sponsor
- Fundación Vacunar
Dengue Fever, Dengue Hemorrhagic Fever
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Primary Objectives: To evaluate safety after each CYD Dengue vaccination in terms of injection site and systemic reactogenicity. To evaluate the occurrence of Serious Adverse Events (SAEs) throughout the trial period.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus, Dengue Diseases
- Trial name
- NCT00880893
- Testing
- CYD Dengue vaccine, NaCl + influenza virus or hepatitis A vaccine
- Where
- 5 sites in Singapore
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Virus, Dengue Fever
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: To describe the humoral immune response to dengue before and after each vaccination with…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00788151
- Testing
- CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine
- Where
- Peru
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever
This study investigates the comparative efficacy of standard treatment plus Ribavirin versus standard treatment alone in preventing clinically significant hemorrhage among patients diagnosed with dengue fever.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Severe Dengue
- Trial name
- NCT06744777
- Testing
- Ribavirin, Standard Treatment
- Where
- 4 sites in Pakistan
- Volunteers
- 284 people
- Sponsor
- Khyber Medical University Peshawar
Dengue Fever
Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are: Is Resomelagon safe to use in patients with Dengue? Is…
- Trial name
- RESOVIR-2 (NCT06917001)
- Testing
- Resomelagon, Standard Treatment
- Where
- 2 sites in Brazil
- Volunteers
- 120 people
- Sponsor
- Federal University of Minas Gerais
Chikungunya Fever
The Pilot Study of Chikungunya Virus Infections in Southern Taiwan
This test is to be collected during the dengue outbreak samples, including samples back in the past and forward to close the case, investigating the prevalence of serum Chikungunya virus infection, and against those suspected…
- Trial name
- NCT02174341
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue Fever
Study of HBV-001 D1 in Healthy Adults
This is a single-center, double-blind, randomized, Phase 1 study to assess the safety and tolerability of HBV-001 D1 in healthy adult subjects.
- Trial name
- NCT00936429
- Testing
- DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hawaii Biotech, Inc.
Dengue Fever
The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia
Dengue infection has been identified as the fastest spreading mosquito-borne viral disease by World Health Organization (WHO), which affects more than 2.5 billion people living in the subtropical and tropical regions.
- Trial name
- NCT02510638
- Where
- Malaysia
- Volunteers
- 322 people
- Sponsor
- Clinical Research Centre, Malaysia
Dengue
Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.
Dengue viral infection and dengue hemorrhagic fever (DHF) are important emerging health problems worldwide. Several candidate dengue vaccines are currently in different stages of development but CYD is the only licensed vaccine…
- Trial name
- DHIT (NCT05476757)
- Testing
- rDEN2Δ30-7169
- Where
- Thailand
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Healthy Volunteers
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine
The purpose of this study is to investigate the immunogenicity and safety of the concomitant administration of TDV (subcutaneous [SC] injection) and of hepatitis A virus (HAV) vaccine (intramuscular [IM] injection) in healthy…
- Trial name
- NCT03525119
- Testing
- TDV, HAV Vaccine
- Where
- 10 sites in United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Response To Dengue Exposure
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine
Background: Dengue is a disease caused by a virus transmitted by mosquitoes in tropical and subtropical regions. Dengue is a leading cause of hospital stays and death in parts of Asia and Latin America, and outbreaks have…
- Trial name
- NCT05691530
- Testing
- rDEN3Δ30/31-7164
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
The aim of the study was to assess the efficacy of Sanofi Pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed dengue cases for dengue-endemic areas of Latin America.
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue
- Trial name
- NCT01374516
- Testing
- Live, attenuated, dengue serotype 1, 2, 3, 4 virus
- Where
- 22 sites in Brazil, Colombia and 3 more
- Volunteers
- 20,869 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Arbovirus Infections
Pilot Survey of Dengue Fever in Solomon Islands
Since 2009, Kaohsiung Medical University Hospital organized a medical team to provide the medical service for people in Solomon Islands thru Taiwan Health Center at the local.
- Trial name
- NCT01868399
- Where
- Taiwan
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital